Felicia Cosman
West Haverstraw, NYNPI 1285766063
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $937,897 of the $1,463,696 with a category attached, or 64.1%. Amgen accounts for 71.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $434,710 and has fallen 54.8% since, to $196,487 in 2025.
Across 1,186 payments — averaging $1234.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1M
- Radius Health, Inc.$379K
- Pfizer$24K
- UCB SA$13K
- Myovant Sciences Inc.$2K
- Lilly USA, LLC$2K
- plus $603 from 1 others
Across 50 payments — averaging $3885.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$134K
- Radius Health, Inc.$59K
- Biocon Biologics Inc$600
What the payments were for
- Consulting fees$293,72620%
- Speaking & faculty fees$937,89764%
- Travel & lodging$200,65114%
- Food & beverage$20,3851%
- Education$11,0371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 735 | $1,043,522 |
| Radius Health, Inc. | 432 | $378,927 |
| Pfizer | 8 | $23,534 |
| UCB SA | 7 | $13,143 |
| Myovant Sciences Inc. | 2 | $2,167 |
| Lilly USA, LLC | 1 | $1,800 |
| Organon | 1 | $603 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.